InvestWiser

Lytix Biopharma AS

LYTIXOslo BørsHealthcareMarket value 615 m NOK
8.00NOK +1.8%
last day · Price as of 19 November 2026

The answer first

Does Lytix Biopharma beat the market?

No, Lytix Biopharma has not beaten the market over the last year.

Lytix Biopharma−21.6%Oslo Børs (OSEBX)+30.6%
  • The ranking · Quality, value and trend combined

    Better than 16% of Nordic stocks

    • Quality61
    • Value2
    • Trend34

    No. 143 of 195 in healthcare

Max for seven days

Follow Lytix Biopharma with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Lytix Biopharma

From today, at a price of 8.00 NOK. Write why you follow Lytix Biopharma, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Lytix Biopharma

Your first answer is free, no account needed.

Do you own Lytix Biopharma, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Lytix Biopharma and a few more. Free, no card.

Past year against the exchange and Super Stock
Lytix Biopharma−21.6%Oslo Børs (OSEBX)+30.6%Super Stock+46.4%
18 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Lytix Biopharma has fallen 21.6% over the past year, including dividends.
  • Overall, Lytix Biopharma ranks better than 16% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 74.8%. The price is 57.0% below its peak now.

What do analysts think of Lytix Biopharma?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

16

Quality, value and trend together. Better than 16% of Nordic stocks.

No. 143 of 195 in healthcare

Quality61
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 105 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.03
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−109.2%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value2
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 184 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity7.2
  • P/SPrice divided by sales925.1
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend34
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 100 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+3.9%
  • 6 months−20.4%
  • 9 months−12.7%
  • 12 months−21.6%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+1.3%
3 years, per year
+11.6%
5 years, per year
−9.7%
Year to date
−19.0%
Largest fall, 3 years
−74.8%
From a peak to the bottom
From the peak now
−57.0%
How far the price is from the peak
Volatility, 1 year
50.5%
How much the price swings over a year
Beta, 1 year
0.54
How much the price moves when the market moves

Return with dividends reinvested.

About Lytix Biopharma

Lytix Biopharma AS is a company in healthcare, listed on Oslo Børs. By market value, Lytix Biopharma is number 10 of 23 companies in healthcare on Oslo Børs. Lytix Biopharma has not paid a dividend in the past twelve months. Of the three measures in the ranking, Lytix Biopharma is strongest on quality, better than 61% of Nordic stocks. The next report from Lytix Biopharma is expected on 11 February 2027. The share trades in NOK. It has around 14 employees.

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc.

See the full analysis of Lytix Biopharma.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Oslo Børs

Explore the stock market